Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients

NCT06888856 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
200
Enrollment
OTHER_GOV
Sponsor class

Conditions

Sponsor

Tel-Aviv Sourasky Medical Center